James Sandy

Mr. Sandy joined F-star as Chief Development Officer (CDO) in March 2022, bringing over 35 years of experience in the pharmaceutical and biotechnology industries across all phases of drug development from clinical trials through regulatory approval. Most recently, Mr. Sandy served as Chief Development Officer at Ellipses Pharma, leading the clinical development of the Company’s portfolio of oncology assets. Previously, he was CDO at Immunocore, and at Creabilis Pharmaceuticals before that. Earlier in his career, he held senior positions at AstraZeneca and at Pfizer, leading development operations teams in Europe and Asia. He holds degrees in Biology and an MPhil in Statistics and Operational Research from Imperial College London.